Login:
 
Metformin improves cardiovascular outcomes in high-risk patients.Practitioner 2013; 257 (1757): 8

Metformin improves cardiovascular outcomes in high-risk patients

28 Jan 2013Pais-up subscribers

Treatment with metformin for three years produced a marked reduction in macrovascular complications and mortality compared with glipizide in patients with type 2 diabetes and coronary artery disease (CAD), a recent trial has shown.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article